PAR-24-207: Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01 - Clinical Trials Optional)
Closed
This grant is closed. A newer notice from the same program is open now: Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01 - Clinical Trials Optional) (PAR-25-299). Status: Due dates in the notice, expires January 7, 2028. It is in our archive of National Institutes of Health notices from 2024.
National Institutes of Health offered grants to nonprofits and colleges and universities. Applications closed on December 5, 2024.
From the official notice on Grants.gov, last changed December 5, 2024. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR01
- Clinical trialsOptional
- R01, Research Project Grant. NIH's standard grant for a defined research project led by a named investigator, usually for up to five years. Other open R01 notices.
Application due dates, page limits and budget limits are set in the notice. Read PAR-24-207 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| PAR-25-299 | December 5, 2024 | Due dates in the notice, expires January 7, 2028 | Open |
Key dates
| Posted | May 13, 2024 |
|---|---|
| Deadline | December 5, 2024 |
| Archived by Grants.gov | January 4, 2025 |
Who can apply
This opportunity was open to nonprofits and colleges and universities.
- Public and State controlled institutions of higher education
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs) ; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Most of the money in the 3 programs behind this notice (70% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This initiative will support multi-level and/or multi-domain intervention research to reduce disparities in liver diseases and liver cancer among populations who experience health disparities in the United States (US).
Who has won Drug Use and Addiction Research Programs grants before
From fiscal 2021 to 2025, Drug Use and Addiction Research Programs (93.279) awarded $7.3 billion across 5,071 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Yale Univ | Connecticut | 150 | $305 million |
| The Johns Hopkins University | Maryland | 156 | $262 million |
| University of California, San Diego | California | 120 | $242 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 100 | $182 million |
| New York University | New York | 62 | $173 million |
Who has won Cancer Cause and Prevention Research grants before
From fiscal 2021 to 2025, Cancer Cause and Prevention Research (93.393) awarded $3.6 billion across 2,517 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 81 | $107 million |
| Sloan-Kettering Institute for Cancer Research | New York | 65 | $99.1 million |
| The Trustees of Columbia University in the City of New York | New York | 48 | $85.3 million |
| Dana-Farber Cancer Institute, Inc. | Massachusetts | 51 | $83.1 million |
| University of North Carolina at Chapel Hill | North Carolina | 49 | $76.1 million |
Who has won Minority Health and Health Disparities Research grants before
From fiscal 2021 to 2025, Minority Health and Health Disparities Research (93.307) awarded $2.0 billion across 1,237 grant awards, an average of $1.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Johns Hopkins University | Maryland | 37 | $69.3 million |
| The Trustees of Columbia University in the City of New York | New York | 25 | $59.1 million |
| University of Hawaii | Hawaii | 18 | $52.8 million |
| The Regents of the University of California, San Francisco | California | 24 | $49.5 million |
| The Morehouse School of Medicine, Inc. | Georgia | 4 | $44.1 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, PAR-25-299, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-24-207 still open?
No. It closed on December 5, 2024. A newer notice is open: PAR-25-299, due dates in the notice, expires January 7, 2028.
Who can apply for Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01 - Clinical Trials Optional)?
National Institutes of Health accepted applications from nonprofits and colleges and universities. The notice adds further conditions, so read its eligibility section.
What is the deadline for Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01 - Clinical Trials Optional)?
Closed December 5, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has won Drug Use and Addiction Research Programs grants before?
The largest recipients over five fiscal years were Yale Univ, The Johns Hopkins University, University of California, San Diego. The program made 5,071 awards worth $7.3 billion in that time.
Similar open grants
- NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)
- NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)
- Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)
- Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)
- Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
- Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)